Eli Lilly's Cymbalta goes generic in December - MNTA wins
Eli Lilly's Cymbalta goes generic in December. Sales of Cymbalta by Lilly are expected to fall from about $5B to $1.5B about 70% drop in sales. MNTA is going to catch a piece of the action (unfortunately, others too, including TEVA) . This seem to predict a bleak outlook for Lilly and an important addition to the bright future of MNTA.
How does MNTA play in this space? MNTA is biosimilars, not small molecule generics.
[Yes, I know copax and lovenox are technically not biologics, but they are still huge complicated drugs that can use MNTA's characterization technologies, not simple chemicals where TEVA et all can clone in minutes.]